20 mL ropivacaine 5 mg/mL + 10 mL ropivacaine 10 mg/mL
ApprovedCompleted 0 watching 0 views this week🔥 Hot
82
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Postoperative Pain
Conditions
Postoperative Pain, Analgesic Efficacy
Trial Timeline
Jun 1, 2009 → Oct 1, 2009
NCT ID
NCT01012232About 20 mL ropivacaine 5 mg/mL + 10 mL ropivacaine 10 mg/mL
20 mL ropivacaine 5 mg/mL + 10 mL ropivacaine 10 mg/mL is a approved stage product being developed by Lundbeck for Postoperative Pain. The current trial status is completed. This product is registered under clinical trial identifier NCT01012232. Target conditions include Postoperative Pain, Analgesic Efficacy.
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01012232 | Approved | Completed |
Competing Products
20 competing products in Postoperative Pain